Skip to content

Medtronic continues quest to ‘close the loop’ on diabetes treatment

4 September 2012

In Medtronic’s continued quest to ‘close the loop’ on treatment for people living with diabetes, we recognise the importance of continuous glucose monitoring (CGM) and the need to improve access to this therapy for Australians living with Type 1 diabetes.

A Continuous Glucose Monitor (CGM) measures and indicates glucose levels continuously (24/7) to assist in monitoring.

Maintaining blood glucose levels within a near-normal range is critical to lowering healthcare costs and improving quality of life for people with type 1 diabetes.

Using the CGM with the pump means readings can be provided every five minutes, allowing for trend analysis of glucose levels in REAL-Time™. For example, patients may choose to be alerted before glucose levels fall ‘too low’ or rise ‘too high’, allowing immediate action to be taken in order to avoid high and low glucose levels.

The Sensor-augmented pump therapy for A1C Reduction Trial, or ‘STAR’ study[i] found that when the CGM was used with the insulin pump, HbA1c levels significantly decreased, without an increase in the rate of hypoglycaemia, which is the biggest challenge with intensive insulin management.

As announced at the Australian Diabetes Educators Association Conference 2012, Medtronic have a special offer for those living with our therapies featuring significant discounts on; CGM Starter Kits including five sensors; and Replacement CGM Kits. For more information contact: 1800 777 808 or australia.diabetes@medtronic.com.

 

This offer is limited to one per Medtronic pump user. Every Medtronic pump user is eligible for one CGM Starter Kit during his pump lifetime and unlimited number of CGM Replacement Kits. Medtronic reserves the right to change the terms and conditions of this offer at any time without prior notice. Individual eligibility criteria may apply.

Please note that wearing your glucose sensor requires ordering, initial training and supervision from your healthcare professionals’ team.

 


[i]Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin pump therapy in type 1 diabetes. NEJM. 2010;363(4):311-320.

 

 

No comments yet

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: